Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial and Pipeline Insight - Fibromyalgia - Approvals legitimize condition and expose underserved patient population (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 07/02/2008
- Report Title: Commercial and Pipeline Insight - Fibromyalgia - Approvals legitimize condition and expose underserved patient population
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 193
Introduction
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, forecasts show the market to grow to over $2.4 billion in 2017.
Scope
*Analysis of clinical trial design and treatment guidelines in fibromyalgia.
*Fibromyalgia market sizing assessment with detailed methodology.
*Detailed profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.
*Case study analysis of Pfizer's launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.
Highlights
The approval of Pfizer's Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.
In June 2008, Eli Lilly's dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.
As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.
Reasons to Purchase
*Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.
*Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.
*Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs.
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, forecasts show the market to grow to over $2.4 billion in 2017.
Scope
*Analysis of clinical trial design and treatment guidelines in fibromyalgia.
*Fibromyalgia market sizing assessment with detailed methodology.
*Detailed profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.
*Case study analysis of Pfizer's launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.
Highlights
The approval of Pfizer's Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.
In June 2008, Eli Lilly's dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.
As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.
Reasons to Purchase
*Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.
*Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.
*Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs.
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
